MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SUL RICONFEZIONAMENTO IN UN NUOVO IMBALLAGGIO E SULLA RIETICHETTATURA DI MEDICINALI IMPORTATI PARALLELAMENTE

marketude Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation, Litigation

[x_icon type="tag"] EU and Competition, Pharmaceuticals and Life Sciences, Litigation

DE BERTI JACCHIA WITH CHARGEURS IN THE ACQUISITION OF SKIRA WITH GITTI AND PARTNERS

marketude Andrea Sonino, Arbitration and ADR, Benedetta Mazzotti, Claudio Corba Colombo, Employment and Pensions, Employment and Pensions, Employment and Pensions, Fashion and Luxury, M&A, Rachele Maggi

De Berti Jacchia team – which assisted Chargeurs Museum Solutions on all legal aspects of the transaction – was headed by the partners Michelangelo Cicogna and Claudio Corba Colombo, assisted by the employment partner Andrea Sonino and the senior associates Rachele Maggi and Benedetta Mazzotti.

DE BERTI WITH EA PHARMA IN THE ACQUISITION OF STARDEA

marketude Andrea Sonino, Arbitration and ADR, Arbitration and ADR, Benedetta Mazzotti, Claudio Corba Colombo, Isabella Basilico, M&A, Michelangelo Cicogna

De Berti Jacchia team – which assisted EA Pharma on all legal aspects, structuring and coordinating the overall transaction – was headed by the Dispute and Employment partner Michelangelo Cicogna, together with the M&A partner Claudio Corba Colombo, assisted by the employment partner Andrea Sonino and the senior associates Benedetta Mazzotti and Isabella Basilico.

ABUSO DI POSIZIONE DOMINANTE NEL MERCATO DEI FARMACI A BASE DI FERRO. LA SVIZZERA VIFOR PHARMA SOTTO INDAGINE DA PARTE DELLA COMMISSIONE

marketude Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications, Publications

[x_icon type="tag"] EU and Competition, Pharmaceuticals and Life Sciences, Litigation

PROPRIETÀ INTELLETTUALE E VACCINI CONTRO IL CORONAVIRUS. LA DECISIONE DELLA WTO SULLA SOSPENSIONE TEMPORANEA DEI MONOPOLI BREVETTUALI PER I VACCINI

marketude Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences, Pharmaceuticals and Life Sciences

[x_icon type="tag"] Intellectual Property, Pharmaceuticals and Life Sciences, Perspectives

LEADERS LEAGUE: RANKED FIRM 2021

marketude Antonella Terranova, Awards, Corporate and Commercial, Employment and Pensions, Gaspare Roma, Guido Callegari, In the Press, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, Intellectual Property, IT & TMT, Maria Cristina Franchini, Michelangelo Cicogna, Michelangelo Cicogna

[br]

DE BERTI JACCHIA VINCE PER GLAXOSMITHKLINE SULLA RESPONSABILITÀ DA PRODOTTI FARMACEUTICI

marketude David Maria Santoro, David Maria Santoro

Sono state pubblicate in rapida successione tre decisioni che hanno definito altrettanti procedimenti giudiziari nei quali De Berti Jacchia, con il partner David Maria Santoro, ha assistito con successo GlaxoSmithKline S.p.A. ed altre società collegate dell’omonimo gruppo farmaceutico anglosassone, ritenute responsabili di danni – patrimoniali e non – legati all’impiego di propri prodotti.

ABUSO DI POSIZIONE DOMINANTE NEL MERCATO DEI FARMACI CONTRO LA SCLEROSI MULTIPLA. TEVA SOTTO INDAGINE DA PARTE DELLA COMMISSIONE

marketude Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives, Perspectives

[x_icon type="tag"] EU and Competition, Pharmaceuticals and Life Sciences, Perspectives

LOTTA CONTRO IL CORONAVIRUS. VIA LIBERA AL QUARTO VACCINO JOHNSON & JOHNSON

marketude Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Coronavirus, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia, Roberto A. Jacchia

[x_icon type="tag"] Coronavirus, EU and General Policies, Pharmaceuticals and Life Sciences, Perspectives

LOTTA CONTRO IL CORONAVIRUS. LA COMMISSIONE APPROVA IL TERZO VACCINO

marketude Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo, Marco Stillo

[x_icon type="tag"] Coronavirus, Pharmaceuticals and Life Sciences

MEDICINALI PER USO UMANO NON SOGGETTI A PRESCRIZIONE MEDICA OBBLIGATORIA. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLE LIMITAZIONI ALLE VENDITE ONLINE

marketude EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition, EU and Competition

[x_icon type="tag"] EU and Competition, Pharmaceuticals and Life Sciences, Litigation